Clinical Trial Update: CardioPET as PET Imaging Agent to Assess Myocardial Perfusion and Fatty Acid Uptake in Known or Suspected CAD Subjects [Phase 2]

View source ↗

Summary

Phase 2 study evaluating CardioPET as a PET imaging agent to assess myocardial perfusion and fatty acid uptake in known or suspected coronary artery disease has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• CardioPET™

Snippet

Sponsor: Fluoropharma, Inc. | Conditions: Coronary Artery Disease | Phase 2 | Status: COMPLETED